Generic Taxol Availability

Taxol is a brand name of paclitaxel, approved by the FDA in the following formulation(s):

TAXOL (paclitaxel - injectable;injection)

  • Manufacturer: HQ SPCLT PHARMA
    Approval date: December 29, 1992
    Strength(s): 6MG/ML [AP]

Has a generic version of Taxol been approved?

Yes. The following products are equivalent to Taxol:

paclitaxel injectable;injection

  • Manufacturer: ACTAVIS TOTOWA
    Approval date: December 9, 2009
    Strength(s): 6MG/ML [AP]
  • Manufacturer: EBEWE PHARMA
    Approval date: December 26, 2007
    Strength(s): 6MG/ML [AP]
  • Manufacturer: EUROHLTH INTL SARL
    Approval date: January 28, 2002
    Strength(s): 6MG/ML [AP]
  • Manufacturer: FRESENIUS KABI ONCOL
    Approval date: November 27, 2006
    Strength(s): 6MG/ML [AP]
  • Manufacturer: ONCO THERAPIES LTD
    Approval date: September 29, 2011
    Strength(s): 6MG/ML [AP]
  • Manufacturer: TEVA PHARMS
    Approval date: January 25, 2002
    Strength(s): 6MG/ML [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Taxol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Taxol.


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
APInjectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.